TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vitamin D Supplementation on In-vitro Fertilization (IVF) Outcomes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Infertile women aged ≤ 38 years undergoing fresh invitro fertilization cycles~Exclusion Criteria:~* Infertile women aged \> 38 undergoing fresh invitro fertilization cycles~* Patients undergoing frozen embryo transfers~* Patients undergoing donor-egg cycles~* Patients who have a contraindication to receiving Vitamin D (e.g. patients with history of primary hyperparathyroidism, sarcoidosis, tuberculosis, kidney disease, or lymphoma)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- patients with Vit D level of < 20ng/mL: Group 1 (Type: None): randomized to receive 400 IU of vitamin D per day
- patients with Vit D levels <20ng/mL: Group 2 (Type: None): Randomized to receive 2000IU of Vitamin D per day
- patients with vit D levels between 20-30 ng/mL: Group 3 (Type: None): Randomized to receiving placebo
- patients with vit D levels between 20-30 ng/mL: Group 4 (Type: None): Randomized to receive 400IU of vitamin D per day
- patients with vit D levels between 20-30 ng/mL: Group 5 (Type: None): Randomized to receive 2000IU of vitamin D per day
- patients with vit D levels > 30ng/mL: Group 6 (Type: None): No treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Falciparum in Pregnancy in Brazil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Gestational age \>16 weeks (determined by LMP and fundal height)- if there is discordance between the two, the more conservative estimate (i.e. lower) will be used, to prevent accidental exposure of a 1st trimester fetus~2. Normal fetal heart beat detected by Doppler~3. Presence of any P. falciparum parasitemia ≤ 50,000 parasites/microliter (thick film)~4. Willing to sign or thumb print informed consent~5. Willing to return for scheduled follow up visits for treatment and observation until delivery~6. Willing to deliver in health facility~Exclusion Criteria:~1. Pregnancy \< 16 weeks~2. Microscopically confirmed P. vivax or mixed infection/ parasitemia (P. falciparum and another species of Plasmodium, i.e. P. vivax, P. ovale, or P. malariae)~3. History of allergy or hypersensitivity to interventional drugs~4. Exposure to antimalarial drugs and other drugs with antimalarial activity within the past 2 months, as determined by history from the woman (quinine, mefloquine, or artemisinin derivatives, including AL and MA)~5. Patients taking drugs with possible interaction with study drugs (ie. warfarin, digoxin)~6. History or family history of epilepsy or psychiatric disorder~7. Presence of signs and symptoms of severe malaria~8. Hemoglobin \< 7 g/dl~9. Inability to tolerate oral medication (repeated vomiting, impairment of consciousness).~10. History of chronic disease including diabetes, renal failure, hepatic failure, heart disease requiring anti-arrhythmic drugs or warfarin, HIV or AIDS, known hemoglobinopathy~11. Participant's inability to return for follow up visits~12. Age \<15 years

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mefloquine- Artesunate (Type: EXPERIMENTAL): Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
- Artemether- Lumefantrine (Type: ACTIVE_COMPARATOR): Artemether-Lumefantrine: 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have rheumatoid arthritis with chronic anemia. Patients must have signed an informed consent~* women must be postmenopausal for at least one year, surgically sterile, or practicing an effective method of birth control, or have a negative serum pregnancy test~* women must not be breast feeding during this study period.~Exclusion Criteria:~* Uncontrolled hypertension~* elective surgery, including joint replacement, anticipated to require transfusion during the extension study period~* thromboembolic event during the double-blind study including acute myocardial infarction, cerebrovascular accident and/or transient ischemic attack~* deep vein thrombosis and/or pulmonary embolism~* uncontrolled psychiatric disease~* planning to be enrolled in any other clinical trial during the course of this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influence of an Inverse Pressure Ramp in Long-term Non-invasive Ventilation on Dyspnea in the Morning After Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Diagnosis of a chronic obstructive pulmonary disease (COPD) with chronic hypercapnic insufficiency~* Therapy with prismaVENT 30, firmware V 3.3 or higher, mode S/T, stable device settings at the time of inclusion without need to adapt ventilation parameters~* May have co-existing obstructive sleep apnea syndrome~* Subjective dyspnea ≥3 (Borg scale) after end of ventilation therapy in the morning~* Written informed consent for study participation including data protection~Exclusion Criteria:~* Missing written informed consent for study participation including data protection~* Contraindication for positive airway pressure therapy~* Use of the softSTOPP feature before study inclusion~* Participation in another study, which influences NIV therapy by defining device settings or titration~* Concomitant oxygen therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- softSTOPP active (Type: ACTIVE_COMPARATOR): None
- softSTOPP inactive (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Veterans~* age 18 and above~* diagnosis of asthma and COPD per guidelines~* for asthma, persistent symptoms per guidelines~* for asthma, a pre-bronchodilator FEV1 55-90% and DLCO 80% predicted~* for asthma, physiologic confirmation by bronchodilator or methacholine challenge~* for COPD, a post-bronchodilator ratio of FEV1/FVC 70% and FEV1 50%~* overall smoking history of \<10 pack-years for asthma and 10 pack-years for COPD.~Exclusion Criteria:~* any use of inhaled corticosteroid for \>2 weeks at a time during the last 6 months, or any use in the last 6 weeks;~* as needed use of nasal steroids in the prior 6 months~* select medications~* recent exacerbation requiring oral or systemic steroids in the past 6 months~* diagnosed vocal cords dysfunction~* other lung diseases (lung cancer, sarcoidosis, tuberculosis, lung fibrosis) or known 1-antitrypsin deficiency~* significant or actively unstable medical or psychiatric illnesses~* diagnosed osteopenia or osteoporosis~* established diagnosis of neuromuscular disease~* BMI 45 kg/m2 and higher~* treated OSA~* pregnancy (confirmed on urine test) or desire to get pregnant in the upcoming 6 months.~* smoking in the past 6 months~* metallic or electronic implants~* claustrophobia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): High dose inhaled fluticasone (1760mcg/day)
- Arm 2 (Type: ACTIVE_COMPARATOR): Low dose inhaled fluticasone (88mcg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage I-III invasive breast cancer~* Awaiting surgery or neoadjuvant treatment~* ECOG performance status 0, 1 or 2~* Adequate organ function~* Prior use of hormone contraception or replacement therapy must have been discontinued at least 30 days prior to diagnostic biopsy (unless participant is willing to undergo an additional biopsy for the study)~Exclusion Criteria:~* Prior or current treatment of any kind for the current breast cancer~* Current use of any other investigational drugs~* Uncontrolled or active infection, congestive heart failure, cardiac arrythmia, or psychiatric illness

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vorinostat and Tamoxifen (Type: EXPERIMENTAL): Vorinostat and tamoxifen are taken for about 14 days prior to definitive surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of the Effect of Vitamin D Supplementation on the Cognitive Function of Older Subjects With Low Levels of This Vitamin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 65 years and older.~* Level of vitamin D (25-OH vitamin D) is less than 30 ng / ml.~* Stable health status as assessed by the treating primary care physician.~* Do not take antidepressant medications.~* Do not take supplements containing vitamin D.~* Normal cognitive function as determined by MoCA Test screening and clinical assessment~* Adequate literacy to enable the performance of assessment instruments~* Provide informed consent as required by the Ethics Committee.~Exclusion Criteria:~* Age younger than 65 years~* Health status not stable as determined by the treating primary care physician~* Cognitive impairment or dementia~* Illiteracy~* Taking supplements containing Vitamin D~* Taking antidepressant medications~* Significant visual or hearing impairment not corrected by spectacles or hearing aids~* Impaired competency limiting the subject's ability to provide informed consent

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group- vitamin D (Type: EXPERIMENTAL): Include patients aged 65 years and older that are found to have below-normal serum levels of vitamin D on routine laboratory testing. After providing informed consent (the study was submitted for approval by the Ethics Committee of the Clalit Health Services) eligible subjects will undergo cognitive and affective assessment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has a clinically suspected and /or bacteriologically documented complicated UTI or acute pyelonephritis judged by the investigator to be serious~* Patient has one positive urine culture within 48 hours of enrollment~* Patient has one or more signs or symptoms of either upper or lower UTI~* Patient is male with or without a bladder catheter or urologic abnormalities; OR patient is a female with a history or clinical evidence of one or more urologic abnormalities~Exclusion Criteria:~* Patient has received any amount of effective concomitant antibiotic therapy after obtaining the urine culture for admission to this study (admission urine culture) and prior to the administration of the first dose of study antibiotics~* Patient's infection has been treated with greater than 24 hours of systemic antibiotic therapy known to be effective against the presumed or documented pathogens within the 72 hour period immediately prior to consideration for entry into the study~* Patient has complete obstruction of any portion of the urinary tract. Patient has a history of seizures other than an uncomplicated febrile seizure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): MK0826 (ertapenem)
- Group 2 (Type: ACTIVE_COMPARATOR): meropenem

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Telehealth Lifestyle Program for Black Adolescent Girls at Risk for Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria for adolescent participants:~* 12-18 years of age~* self-identify as Black or African American~* have obesity~Exclusion Criteria of adolescent participants:~* pregnant or within 3 months postpartum.~* participated in a formal weight management program within 6 months prior to study.~* currently taking medications or diagnosed with a condition known to influence metabolism, physical activity ability, or cognitive function.~* have previously undergone bariatric surgery.~* have type 2 diabetes.~* unable to speak English or have developmental conditions that interfere with ability to communicate.~Inclusion criteria of caregiver participants:~* 18 years or older.~* proficiency in speaking English.~* live in the same household as the adolescent who will also be enrolled~* prepares the majority (\>50%) of meals in the household~Exclusion Criteria of caregiver participants:~* pregnant or within 3 months postpartum.~* unable to speak English or have developmental conditions that interfere with ability to communicate.

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Intervention Adolescents-Caregiver Dyads (Type: EXPERIMENTAL): Adolescent-caregiver dyads receive 12 week telehealth lifestyle program consisting of a Wellness session, Cooking Experience, and Dance Classes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of HD~* Symptoms of dysphagia~* Must be able to swallow tablets~Exclusion Criteria:~* Other confounding diseases that affect swallowing~* Depression~* Hepatic impairment~* Renal impairment~* Dementia

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deutetrabenazine (Type: EXPERIMENTAL): The participants randomized to this group will receive oral deutetrabenazine for 8 weeks. Week 1: 6 mg once daily; Week 2: 6 mg twice daily (BID); Week 3: 9 mg BID; Week 4: 12 BID; Week 5: 15 mg BID; Week 6: 18 mg BID; Week 7: 21 mg BID; Week 8: 24 mg BID.
- Placebo (Type: PLACEBO_COMPARATOR): The participants randomized to this group will receive oral placebo for 8 weeks. Week 1: 6 mg once daily; Week 2: 6 mg twice daily (BID); Week 3: 9 mg BID; Week 4: 12 BID; Week 5: 15 mg BID; Week 6: 18 mg BID; Week 7: 21 mg BID; Week 8: 24 mg BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial Comparing Prevena and ActiV.A.C. System to Convetional Care After Bascom's Cleft Lift Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with recurrence after previous surgery for pilonidal disease, cases of poor postoperative healing (\> two months) or primary extensive/fistulating disease referred to Randers Regional Hospital for assessment for reconstructive BCL surgery.~Exclusion Criteria:~Patients under 18 years of age~* Patients who smoke (not offered this type of surgery), ceased min. 6 weeks pre-operatively~* Patients with PS lesions are ≤ 3 cm from the anus~* Patients with allergies to Silver or acrylic~* Patients who cannot adhere to study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prevena (Type: EXPERIMENTAL): Patients randomized to application of Prevena ™ and ACTIV.A.C ™ Therapy System 4-7 days post-operatively. Patients will return to the surgical day clinic to have the system removed either at day 7 or when/ if function ceases. Patients receive 3 days oral antibiotics postoperatively (Ciproxin 250 mg x 2 and Metronidazole 500 mg x 3). Sutures are removed at clinical control after 14 days and patients are seen again by BCL surgeon after 3 months and are discharged when completely healeddrainage and conventional wound dressing
- Conentional postoperative care (Type: NO_INTERVENTION): patients randomized to convetional postoperative regime with a penrose drain (passive) and a dry draping for 24 hours and after usage of sanitary pads. Patients receive 3 days oral antibiotics postoperatively (Ciproxin 250 mg x 2 and Metronidazole 500 mg x 3). Drain is removed after 24 hours and Sutures are removed at clinical control after 14 days and patients are seen again by BCL surgeon after 3 months and are discharged when completely healeddrainage and conventional wound dressing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Proof of primary varicella infection (chicken pox) either by appropriate history (as defined by ACIP) or otherwise confirmed with a positive VZV IgG antibody level~2. Patient has a history of ulcerative colitis (UC) diagnosed by standard clinical, radiographic, endoscopic, and histopathologic criteria~3. Patient is receiving one of the following treatments for their UC:~Group A: Tofacitinib monotherapy, Group B: Anti-TNF monotherapy (adalimumab, golimumab, certolizumab pegol, infliximab), Group C: Anti-TNF combination therapy with a thiopurine (6 mercaptopurine, azathioprine), Group D: 5-aminosalicylates or other non-immunomodulatory therapy.~Exclusion Criteria:~1. Previous receipt of any HZ vaccine~2. Allergy to zoster vaccine or a component of the vaccine~3. Other underlying chronic medical conditions that could affect immunogenicity to vaccines (rheumatoid arthritis, psoriasis etc.)~4. History of herpes zoster infection or post herpetic neuralgia~5. Patient cannot or will not provide written informed consent~6. Patient is on a non-licensed or experimental immunomodulator~7. Patient is on methotrexate~8. Patient has received immunoglobulin therapy or blood products with the past month~9. Currently pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- UC patients on tofacitinib monotherapy (Type: EXPERIMENTAL): Ulcerative Colitis patients on Tofacitinib monotherapy, all patients will be treated with the standard Tofacitinib and will receive Shingrix vaccine.
- UC patients on anti-TNF monotherapy (Type: ACTIVE_COMPARATOR): Ulcerative Colitis patients on anti-TNF monotherapy, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab)and will receive Shingrix vaccine.
- UC patients on anti-TNF and a thiopurine (Type: ACTIVE_COMPARATOR): Ulcerative Colitis patients on anti-TNF and a thiopurine, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab) and thiopurine (6-mercaptopurine, azathioprine) and will receive Shingrix vaccine.
- UC pts. on aminosalicylates or off immunomodulatory therapy (Type: ACTIVE_COMPARATOR): Ulcerative Colitis patients on non-immunosuppressive therapy or 5-aminosalicylates, all patients will be treated with the standard non-immunosuppressive therapy or 5-aminosalicylates and will receive Shingrix vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues